Chemomab Therapeutics Ltd (NASDAQ:CMMB) CEO Dr Adi Mor talked with Proactive's Stephen Gunnion about recent advancements in Chemomab's mission to treat rare fibrotic diseases, focusing on primary sclerosing cholangitis (PSC).
Following the release of the company's third-quarter results, Mor shared that Chemomab’s lead candidate, CM-101, a drug targeting inflammation and fibrosis, recently delivered positive topline results in a Phase 2 clinical trial. “We are targeting rare diseases with large commercial potential and high unmet medical need,” she noted, highlighting Chemomab's strategic approach.
In a significant milestone, Chemomab will meet with the FDA by the end of this year to finalise plans for a Phase 3 pivotal study, which could mark a transformative phase for the company and the PSC treatment landscape. Mor pointed out the potential for FDA acceptance of noninvasive biomarkers as registration endpoints, indicating substantial de-risking for CM-101. She also shared updates on Chemomab’s extended study on PSC, expected to deliver additional data by Q1 2025.
Mor highlighted the commercial potential in treating PSC, noting there are no approved drugs for this condition that affects approximately 80,000 patients in major markets. Additionally, Chemomab recently raised $10 million, securing its financial runway into 2026, aided by support from top-tier investors like OrbiMed and new partners such as HBM Partners and Sphera. This capital will fund upcoming milestones, as well as further development for CM-101.